This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

AlerisLife Valuation

Is FSQA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FSQA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate FSQA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate FSQA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FSQA?

Key metric: As FSQA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for FSQA. This is calculated by dividing FSQA's market cap by their current revenue.
What is FSQA's PS Ratio?
PS Ratio	0.3x
Sales	US$159.70m
Market Cap	US$44.14m

FSQA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	-2.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does FSQA's PS Ratio compare to its peers?

The above table shows the PS ratio for FSQA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.8x
MAK Maternus-Kliniken	0.3x	n/a	€33.6m
JTH Gesundheitswelt Chiemgau	0.3x	n/a	€24.4m
MED MEDICLIN	0.2x	0.7%	€124.5m
LIK LIMES Schlosskliniken	2.3x	17.7%	€96.2m
FSQA AlerisLife	0.3x	68.9%	€44.1m

Price-To-Sales vs Peers: FSQA is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.3x).

Price to Sales Ratio vs Industry

How does FSQA's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
EIF MedNation	0.1x	n/a	US$5.23m
TLIK Arzneiwerk VIDA	0.08x	n/a	US$4.80m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: FSQA is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Healthcare industry average (0.7x)

Price to Sales Ratio vs Fair Ratio

What is FSQA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FSQA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	7.2x

Price-To-Sales vs Fair Ratio: FSQA is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (7.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

-5.3%

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

-10.5%

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

0.5%

-82.5%